Integra LifeSciences Holdings Corporation has entered into an amendment to its existing corporate loan agreement, originally established on March 24, 2023. The amendment, dated June 6, 2025, involves a syndicate of lending banks including Bank of America, Citibank, JPMorgan Chase, and others. While the amendment does not increase Integra's total indebtedness, it introduces temporary changes during a Covenant Relief Period. These changes include a revised applicable rate schedule and restrictions on certain investments, incremental indebtedness, and transactions involving intellectual property. The amendment aims to provide Integra with financial flexibility while maintaining compliance with its existing credit arrangements.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Integra LifeSciences Holdings Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000917520-25-000060), on June 09, 2025, and is solely responsible for the information contained therein.